At CPHI Frankfurt 2025, as 66,000 delegates filled the halls and 260 speakers dissected the future of pharma, one statistic cut through the noise like a thunderclap: 118 biologics will lose patent protection by 2034, unlocking a $234 billion opportunity. Yet, as of now, only a dozen has biosimilars in active development.
That gap — between what’s coming and who’s ready — may be the most valuable whitespace in modern pharmaceuticals. And it tells the story of an industry standing at its most dramatic inflection point since the Hatch–Waxman Act of 1984.
Act I: The end of easy money
“Change is the law of life. And those who look only to the past or present are certain to miss the future.”
— John F. Kennedy
For decades, generics were the industry’s dependable cash machine — scale up, compete on price, ride the erosion curve, repeat. But by 2035, the rules will be unrecognizable.
Plain, commoditized trade generics — once the heart of the business — are becoming an economic dead end. Margins in the US and EU are collapsing toward 30 per cent variable cost, 20 per cent gross contribution, and single-digit EBITDA. Only the leanest, most frugal operators will survive, mostly “no-frills” players from India and China.
For everyone else, the game has shifted from volume to value. As one senior executive quipped in Frankfurt, “We’ve trimmed the tail, now we need to grow a spine.”
Act II: The biosimilar gold rush
“In the middle of difficulty lies opportunity.”
— Albert Einstein
If you want to see where the next fortune lies, follow the biologics. Between 2025 and 2035, the global biosimilars market will more than double — from $35 billion to $72 billion. Recent launches routinely capture 60–80 per cent market share within three years.
When Keytruda, the world’s most lucrative cancer drug, loses European exclusivity in 2031, the first biosimilar to hit the market could be worth tens of billions. But here’s the rub: despite the vast opportunity, development pipelines remain shockingly thin. Only 12 biosimilars are currently in motion for that pool of 118 expiring biologics.
That’s not just an opportunity — it’s a race. And the starting gun is being fired by artificial intelligence.
Act III: The Rise of machines
“The future belongs to those who prepare for it today.”
— Malcolm X
In 2025, the FDA quietly rolled out “Elsa,” an AI-driven regulatory platform that performs in minutes what once took three days — analyzing complex submission packages, cross-checking data, and predicting review outcomes. Companies leveraging AI for filings now report 80 per cent faster processing with 90 per cent accuracy.
That’s not incremental improvement — it’s time compression on an industrial scale.
When months equal billions, speed becomes the ultimate competitive weapon. In this new landscape, it’s not just about who develops the biosimilar first, but who gets it approved first. The winners will be those who blend biotechnology with digital velocity — who marry R&D muscle with algorithmic precision.
Act IV: Seven shifts
redefining pharma
“Strategy is about making choices, trade-offs; it’s about deliberately choosing to be different.”
— Michael Porter
Across the global pharma landscape, every major player seems to be striking the same chords—different rhythms, same melody. The industry’s giants are not just reacting to change; they’re composing an entirely new score for survival.
Breaking free from
commodities
The era of plain generics is fading fast. Companies like Teva, Sandoz, and Viatris are steering their portfolios toward biosimilars, specialty therapies, and value-added medicines. The logic is simple: price competition has hit the floor, and differentiation—scientific or strategic—is now the only way up.
Portfolio precision
After years of chasing volume, firms are trimming their product lines with surgical precision. The goal isn’t to sell more, but to sell smarter. By cutting underperforming SKUs and freeing up manufacturing bandwidth, companies are rebuilding their margin structure from the inside out.
Operational mastery
Efficiency is no longer just about cost-cutting; it’s about resilience. Leaner networks, optimized procurement, and data-driven plant operations are replacing legacy sprawl. The new mantra: fewer factories, stronger control, and zero waste.
R&D with a stopwatch
Gone are the days of sprawling research budgets and decade-long pipelines. The modern R&D engine is agile and sharply targeted—focused on fast-track programs, complex generics, and incremental innovation that reaches patients (and payers) sooner. The winners are those who can translate science into market speed.
Global footwork
The U.S. may still dominate in revenue, but it’s no longer the only battlefield. Europe, Canada, Mexico, and Brazil are becoming strategic laboratories for new launches and pricing models. In these regions, predictability and regulatory pragmatism often trump Washington’s volatility.
Capital with a conscience
In a capital-intensive business, cash discipline has become a competitive edge. Buybacks and empire-building are giving way to deleveraging, selective M&A, and sharper allocation. It’s not about who spends more—it’s about who spends wisely.
AI in the shadows
Artificial intelligence is on every PowerPoint slide but in few actual systems. Most companies are still experimenting, not integrating. But those that embed AI deeply—across R&D, supply chain, and regulatory filings—will soon discover what others are only talking about: that in pharma’s next decade, time is the ultimate currency.
Act V: Innovation on a budget
“Innovation is not about saying yes to everything. It’s about saying no to all but the most crucial features.”
— Steve Jobs
This isn’t Silicon Valley. Pharma moves with regulation, not adrenaline. For many companies, especially mid-tier and emerging-market players, the pivot toward high-value segments is daunting.
The barriers are high — capital intensity, regulatory complexity, and the need for long-term R&D discipline. But the logic is inescapable.
To stay relevant, firms must:
Control costs like manufacturers, Focus portfolios like investors, Invest in R&D like innovators, and Integrate digital tools like tech companies.
That’s “innovation on a budget” — not moonshot science, but strategic engineering of what already works.
Act VI: Health sovereignty and new supply chain
“We don’t rise to the level of our expectations; we fall to the level of our systems.”
— Archilochus (popularized by James Clear)
There’s another subplot unfolding: who will actually make the world’s medicines?
As Europe and the US offload commoditized production to Asia, questions of health sovereignty are resurfacing. Covid-19 exposed the fragility of global supply chains, and governments are increasingly uncomfortable with dependence on distant suppliers for essential medicines.
The challenge ahead will be to reconcile two competing truths:
Commoditized generics are still essential for global access and affordability.
High-cost geographies can’t sustain producing them profitably.
The next decade will demand creative industrial policy — incentives for regional manufacturing, smarter inventory systems, and AI-driven production planning to reduce working capital pressure. In short, sovereignty will require software as much as steel.
Act VII: The rebuild
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
— Charles Darwin
What we’re witnessing isn’t the death of generics; it’s a full-scale rebuild. The industry is unlearning decades of muscle memory.
As one panelist at CPHI put it, “Generics taught us efficiency; biosimilars will teach us precision.”
Teva is betting on innovative neurology products. Sandoz is doubling down on European biosimilars. Viatris is still searching for its post-merger identity. Indian giants like Dr. Reddy’s, Lupin, and Cipla are pruning trade generics to free cash for complex products.
Different strategies, one destination: a smaller, sharper, smarter industry.
By 2035, the pharma map will look completely different — a few global giants dominating biosimilars and specialty niches, a handful of ultra-lean commodity producers, and a middle tier that either merged, reinvented, or disappeared.
The shift is painful but inevitable. In an age where AI can shrink regulatory cycles and biologics define the next trillion dollars of market value, there’s no room for complacency.
Curtain call
The generics industry was once defined by replication. Its next chapter will be defined by reinvention.
The companies that survive the next decade will be those that understand a new truth: speed, focus, and differentiation aren’t luxuries — they’re lifelines.
In this story, the plot twist isn’t that generics are dying. It’s that they’re evolving — into something far more complex, far more competitive, and far more intelligent.
And the clock, powered by AI, is already ticking.
(The author is Senior Director at Boehringer Ingelheim. She is also on the advisory board of the CPHI conference board and editorial board) |